CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer
Lei Nie(Xinyang Normal University), Mien‐Chie Hung(Precision Therapeutics (United States)), Baozhen Ke(The University of Texas MD Anderson Cancer Center), Jun Yao(The University of Texas MD Anderson Cancer Center), Gabriel N. Hortobágyi(The University of Texas MD Anderson Cancer Center), Jennifer L. Hsu(The University of Texas MD Anderson Cancer Center), Cihui Zhu(The University of Texas MD Anderson Cancer Center), Yi‐Hsin Hsu(The University of Texas MD Anderson Cancer Center), Nancy E. Davidson(WinnMed), Rong Deng(The University of Texas MD Anderson Cancer Center), Celina G. Kleer(University of Michigan), Xixi Zhao(Unknown), Li-Chuan Chan(The University of Texas MD Anderson Cancer Center), Jung-Mao Hsu(China Medical University), Hirohito Yamaguchi(China Medical University), Fei Zhang(Northeast Agricultural University), Ye Han(Sungkyunkwan University), Yi Yang(The University of Texas MD Anderson Cancer Center), Wan-Chi Lin(The University of Texas MD Anderson Cancer Center), Jun Tang(Hubei University of Medicine), Yu‐Yi Chu(The University of Texas MD Anderson Cancer Center), Junwei Hou(National Vaccine and Serum Institute), Yongkun Wei(The University of Texas MD Anderson Cancer Center), How-Wen Ko(University of Houston), Dean Pan(Austin College), Weiya Xia(The University of Texas MD Anderson Cancer Center), Longfei Huo(The University of Texas MD Anderson Cancer Center)
Cited by 99
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
|Cancer Cell|2004|1.9k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
|Nature Communications|2016|1.1k